Eli Lilly has filed lawsuits against three medical spas and online vendors for selling products claiming to contain tirzepatide, the active ingredient in its weight-loss drug Zepbound. The lawsuits, citing false advertising and safety risks, target Pivotal Peptides, MangoRx, and Genesis Lifestyle Medicine, with Lilly seeking court orders to halt their sales and unspecified monetary damages. The company emphasizes that these actions aim to protect consumers from misleading claims and untested formulations.